J.P. Morgan To Reduce Estimates And Maintain Neutral Rating For Mako Surgical

According to J.P. Morgan, Mako Surgical MAKO is reducing its estimates. J.P. Morgan reported that, following 4Q results, it is updating its Mako model and maintaining the Neutral rating. “Mako reported 4Q10 results that were in line with the company's previously announced metrics, including 13 domestic system sales in the quarter and 1,146 implants. Revenue of $14.8M was $2.1M below the Street consensus, due to a change in revenue recognition at the system sales line, which reduced 4Q revenues by $2.2M. Mako reported a loss per share of $0.26, versus the Street's ($0.20) forecast.” Mako Surgical closed yesterday at $20.08.